The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis
Abstract
Because of the major difficulties in measuring clinical end points in multiple sclerosis (MS) treatment trials, there has been much enthusiasm for using magnetic resonance imaging (MRI) findings as an alternative outcome. To provide international consensus guidelines for the use of MRI in MS clinical trials, a task force of the US National MS Society was convened. The recommendations of the task force are presented in this review. Given the high sensitivity for detecting pathological activity in relapsing‐remitting and secondary progressive MS, monthly T2‐weighted and gadoliniumenhanced brain MRI is an excellent tool for short‐term exploratory trials of new agents where it serves as the primary end point; in particular, failure to demonstrate a reduction in lesion activity avoids the time, cost, and risks of a larger clinical end point study. However, conventional MRI findings have a limited correlation with disability in established MS. The primary end point of a definitive trial should therefore be clinical, although serial MRI at 6‐ to 12‐month intervals is a useful secondary end point in providing an index of pathological progression. In trials of patients presenting with clinically isolated syndromes suggestive of MS, MRI findings can be used in the entry criteria, and as a secondary outcome measure, but conversion to clinically definite MS should be the primary outcome. The pathological substrates of irreversible disability are demyelination and axonal loss. Putative magnetic resonance markers for these processes include decreased N‐acetylaspartate on proton magnetic resonance spectroscopy, decreased magnetization transfer ratios, hypointensity on T1‐weighted images, and loss of short T2 water fractions, some of which relate more closely to disability than conventional MRI findings. Further technical developments should lead to more accurate quantitation, greater pathological specificity, and stronger clinical correlations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“With regard to APOE genotype, our results are in agreement with those of Growdon et al [41, 42] who found that while the prevalence of APOE ∈4 was greater in AD patients than controls, the rate of clinical progression in patients with established AD was not different for ∈4 carriers vs ∈4 non-carriers.”
From Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease (1998) · cites this paper as [42]
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Self-citationAutomatic 3D intersubject registration of MR volumetric data in standardized Talairach space
Collins, D. L., Neelin, P., Peters, T. M., & Evans, A. C. (1994) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-199403000-00005 · Cited by 3,431
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis
The IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.655 · Cited by 2,085
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis
Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,964
Self-citationInterferon beta‐lb in the treatment of multiple sclerosis
The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1995) · Neurology · doi:10.1212/wnl.45.7.1277 · Cited by 971
In vivo visualization of myelin water in brain by magnetic resonance
MacKay, A. L., Whittall, K. P., Adler, J., Li, D. K. B., Paty, D. W., & Graeb, D. A. (1994) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910310614 · Cited by 916
Self-citationDousset, V., Grossman, R. I., Ramer, K., Schnall, M. D., YOUNG, L. H. Y., González‐Scarano, F., Lavi, E., & Cohen, J. A. (1992) · Radiology · doi:10.1148/radiology.182.2.1732968 · Cited by 689
Beck, R. W., Cleary, P. A., Trobe, J. D., Kaufman, D. I., Kupersmith, M. J., Paty, D. W., & Brown, C. H. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312093292403 · Cited by 573
Self-citationSerial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions
Davie, C. A., Hawkins, C. P., Barker, G. J., Brennan, A., Tofts, P. S., Miller, D. H., & McDonald, W. I. (1994) · Brain · doi:10.1093/brain/117.1.49 · Cited by 536
Self-citation
Research works printed but not linked: 12
- Barkhof F, 1992, Relapsing‐remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in deterniining dissase activity, Am J Radiol, 159, 1041
- Campi A, 1995, Acute trmsverse myelopathy: spinal and cranial MR study with clinical follow‐up, AJNR, 16, 115
- Tas MW, 1995, The effect of gadolinium on the sensitivity and specificity of MR imaging in the initial diagnosis of multiple sclerosis, AJNR, 16, 259
- Barkhof F, 1995, Towards specific magnetic resonance imaging criteria in the early diagnosis of multiple sclerosis, Neurology, 45, A338
- Davie CA, 1994, Proton magnetic retonance spectroscopy (MRS) study of cerebellar dysfunction in multiple sclerosis, J Neurol, 341, s151
- Hiehle JF, 1995, Magnetization transfer effect in MR‐detected multiple sclrrosis lesions: comparison with gadolinium‐enhanced spin‐echo images and non‐enhanced T1‐weighted images, AJNR, 16, 69
- Dousser V, 1995, Lysolecithin‐induced demyelination in primates: preliminary) in vivo study wirh MR and magnetization transfer, AJNR, 16, 225
- Berry DA, 1990, Statistical methodology in the pharmaccutical sciences, 1
- Simon JH, 1995, The natural histry of MS based on an annual MR snapshot: results from the MSCRG study of inttamuscular recombinant interferon beta‐la, Neurology, 45, A418
- Mathews VP, 1994, Cerebral infarction: effects of dose and magnerization transfer saturation at gadoliniunm‐enhanced MR imaging, Ridiology, 190, 547
- Filippi M, 1994, Inter‐tater variability of brain MRI lesion volume measurements in multiple sclerosis, Proc Soc Magn Reson, 1, 167
- Grimaud J, 1995, Evaluation of computer assisted quantification of MS lesions in cranial MRI, J Neurol Neurosurg Psychiatry, 58, 215
Cited by
Sorted by citations
Items 401–440 of 440
Magnetic Resonance Imaging Techniques in Phase III Clinical Trials in Multiple Sclerosis
Paty, D. W., & Li, D. K. B. (1999) · Springer eBooks · doi:10.1007/978-88-470-2153-2_9 · Cited by 1
Self-citationIntérêt du recalage automatique des IRM cérébrales dans le suivi des scléroses en plaques
Lebrun‐Frénay, C., Rey, D., Chanalet, S., Bourg, V., Bensa, C., Chatel, M., Ayache, N., & Malandain, G. (2004) · Revue Neurologique · doi:10.1016/s0035-3787(04)71034-6 · Cited by 1
Donoghue, S. (1996) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.5.10.1349 · Cited by 1
MRI and assessment of treatment in multiple sclerosis
Miller, D. H. (2001) · Brain · doi:10.1093/brain/124.5.1052 · Cited by 1
Self-citationMethylprednisolone for Acute Relapses of Multiple Sclerosis
Uitdehaag, B. M. J., & Barkhof, F. (1998) · CNS Drugs · doi:10.2165/00023210-199810040-00001 · Cited by 1
Self-citationCytokine-Based Therapeutics for Intrinsic CNS Disease Processes
Wiendl, H., & Hohlfeld, R. (2005) · CRC Press eBooks · doi:10.1201/9781420039849.ch14 · Cited by 1
Clinical Magnetic Resonance Spectroscopy
Hecke, P. V. (2001) · Medical radiology · doi:10.1007/978-3-642-56662-2_5 · Cited by 1
On genetics and transcriptomics of multiple sclerosis
Brynedal, B. (2009) · Figshare
Schluep, M., & Bogousslavsky, J. (2001) · Blue books of practical neurology · doi:10.1016/s1877-3419(09)70018-2
Moraal, B. (2010) · Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam)
Statistical Approaches to the Use of Magnetic Resonance Imaging Data for Clinical Trials
Bruzzi, P., & Sormani, M. P. (1999) · Springer eBooks · doi:10.1007/978-88-470-2153-2_11
Multipl Skleroz TanısındaMagnetik Rezonans Görüntülemenin Yeri
Karagöz, E. (2001) · Turkiye Klinikleri Tip Bilimleri Dergisi
Molekulare Aspekte der Behandlung der Multiplen Sklerose
Mitrovic, B., Stock, G., Perez, H. D., & Dinter, H. (1999) · Springer eBooks · doi:10.1007/978-3-662-07096-3_14
Putative biomarkers of neuro-restoration in the CNS
Gnanapavan, S. (2013) · UCL Discovery (University College London)
Mesaroš, Š., Drulovic, J. S., Stojsavljević, N., & Lević, Z. (2002) · Srpski arhiv za celokupno lekarstvo · doi:10.2298/sarh0206226m
Nuevas aplicaciones diagnósticas de la resonancia magnética en neurología
Rovira, À. (2002) · Medicina Clínica · doi:10.1016/s0025-7753(02)72516-5
Neue MRT-Techniken zur Bewertung des Therapieeffekts in Studien und in der Praxis?
Fazekas, F., Ropele, S., Enzinger, C., Khalil, M., Wallner-Blazek, M., Seifert‐Held, T., Storch, M. M. L., Archelos, J. J., & Fuchs, S. C. P. C. (2010) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Magnetic Resonance Imaging Predictors for Disability in Multiple Sclerosis
Minneboo, A. (2008) · Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam)
Nierga, I. P. (2004) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Review of the Results of Previous Phase II, Magnetic Resonance Imaging-monitored Clinical Trials
Sørensen, P. S. (1999) · Springer eBooks · doi:10.1007/978-88-470-2153-2_8
Slowing the Progression of Multiple Sclerosis
Rudick, R. A. (2005) · Elsevier eBooks · doi:10.1016/b978-012738903-5/50005-9
Measuring multiple sclerosis rehabilitation outcomes
Cano, S., & Hobart, J. C. (2006) · CRC Press eBooks · doi:10.1201/b14373-6
T2w subtraction MR imaging in phase II MS trials: a powerful new outcome measure
Moraal, B., van den Elskamp, I. J., Knol, D. L., Uitdehaag, B. M. J., Geurts, J. J. G., Vrenken, H., Pouwels, P. J. W., van Schijndel, R. A., Meier, D., Guttmann, C. R. G., et al. (2009) · Pure Amsterdam UMC
Self-citationTóth, E. M. (2019) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.10259
Pharmacological and clinical profile of IFNβ-1a (Avonex®IM Injection Syringe 30μg)
Sumino, R. (2007) · Folia Pharmacologica Japonica · doi:10.1254/fpj.129.209
Multiple Sclerosis: Experience with Large Clinical Trials
Cookfair, D. L., Weinstock‐Guttman, B., & Cohen, J. A. (2001) · Springer eBooks · doi:10.1007/978-1-4471-3787-0_32
Thorpe, J. W. (1999) · UCL Discovery (University College London)
Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination
Tenser, R. B., Miller, D. H., Thompson, A. J., & Sailer, M. (1999) · Neurology · doi:10.1212/wnl.53.8.1893
Self-citation(1998) · Rivista di Neuroradiologia · doi:10.1177/19714009980110s128
Some modern methods of diagnosis and pathogenetic therapy of multiple sclerosis
Stolyarov, I. D., Бисага, Г. Н., Вотинцева, М. В., Ilves, A. G., Nikiforova, I. G., Nikolaeva, N. V., Rudas, M. S., Petrov, A. M., Прахова, Л. Н., Totolyan, N. A., et al. (2002) · Neurology Bulletin · doi:10.17816/nb87566
(2006) · Elsevier eBooks · doi:10.1016/b978-0-443-07271-0.50022-7
(2006) · Wiley eBooks · doi:10.1002/9780470041000.cedt081
Sandrock, A. W., & Rudick, R. A. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511980053.011
Simon, J. H., Jacobs, L. D., & Campion, M. (1998) · Annals of Neurology · doi:10.1002/ana.410440329
Self-citationRistori, G., Perna, A., Montesperelli, C., Battistini, L., Bomprezzi, R., Cannoni, S., Borsellino, G., Pozzilli, C., Buttinelli, C., & Salvetti, M. (1999) · Springer eBooks · doi:10.1007/978-88-470-2269-0_5
Perspektiven der klinischen Multiple-Sklerose-Forschung und -Therapie
Goebels, N., Wiendl, H., & Hohlfeld, R. (2001) · Springer eBooks · doi:10.1007/978-3-642-59453-3_5
Cendrowski, W. (2010) · DOAJ (DOAJ: Directory of Open Access Journals)
Wawrzyniak, S., & Maciejek, Z. (2010) · DOAJ (DOAJ: Directory of Open Access Journals)
Wansapura (1999) · doi:10.1002/(sici)1522-2586(199904)9:4
Metadata
- Authors
- Miller, D. H., Albert, P. S., Barkhof, F., Francis, G., Frank, J. A., Hodgkinson, S., Lublin, F. D., Paty, D. W., Reingold, S. C., & Simon, J.
- Affiliations
- UCL Queen Square Institute of Neurology (GB)
- National Institutes of Health (US)
- Montreal Neurological Institute and Hospital (CA)
- Liverpool Hospital (AU)
- University of British Columbia (CA)
- National Multiple Sclerosis Society (US)
- University of Colorado Health (US)
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 1996-01
- Volume
- 39
- Issue
- 1
- Pages
- 6-16
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2030792741
- Cited by
- 444
- References
- 83
- Citations by year
- 2025: 1 · 2023: 1 · 2022: 2 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 4 · 2016: 3 · 2015: 2 · 2014: 6 · 2013: 5 · 2012: 9
- FWCI
- 56.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Keywords
- multiple sclerosis, magnetic resonance imaging, treatment monitoring, clinical trial endpoints, relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis, clinically isolated syndrome, disability progression, demyelination, axonal loss, N-acetylaspartate, magnetization transfer ratio, T2-weighted MRI, gadolinium-enhanced MRI, MRI outcome measures
- MeSH terms
- Clinical Trials as Topic, Persons with Disabilities, Humans, Magnetic Resonance Imaging, Multiple Sclerosis, Magnetic Resonance Spectroscopy, Sensitivity and Specificity, Treatment Outcome, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
